新药时代多发性骨髓瘤的巩固、维持和持续治疗  

Consolidation, maintenance and continuous therapy for multiple myeloma in the era of novel agents

作　　者：朱婉秋[1] 陈文明[1] 

机构地区：[1]首都医科大学附属北京朝阳医院血液科北京市多发性骨髓瘤医疗研究中心,100020

出　　处：《肿瘤研究与临床》2016年第8期561-565,共5页Cancer Research and Clinic

基　　金：国家自然科学基金（81500164）

摘　　要：随着新药和大剂量化疗联合自体造血干细胞移植的应用,多发性骨髓瘤（MM）患者生存期显著延长.但由于骨髓瘤生物学特性及初始治疗后微小残留病的存在,大部分MM患者的病程都呈现为一系列“缓解-复发”循环模式.因此需对移植后的MM患者进行巩固、维持治疗,对高龄、不适合移植的MM患者进行持续治疗.文章对新药时代MM的巩固、维持和持续治疗的研究进展进行综述.With the application of novel agents and high-dose chemotherapy with autologous stem cell transplantation（ASCT）,the survival time of multiple myeloma（MM） has been significantly prolonged.However,due to the biological characteristics of myeloma and minimal residual disease after initial treatment,the disease courses of most MM patients show a series of remissions and relapses.Hence,it is necessary to apply consolidation and maintenance therapy after ASCT and continuous therapy for transplant-ineligible patients.This paper reviews the advances in consolidation,maintenance and continuous therapy for MM in the era of novel agents.

关 键 词：多发性骨髓瘤 巩固治疗 维持治疗 持续治疗 

分 类 号：R733.3[医药卫生—肿瘤]